Clinical Trial Search

Primary: Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis. — 14.3; 66.4; 64.5 Percentage of Subjects…

Primary: Plaque Index — 2.45; 2.22; 2.54; 2.56 Units on a scale — p=0.05

Primary: Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations — 34.428; 132.075 μg/mL

Primary: Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women — 6.04; 1.65 percentage change in lumbar spine BMD…

Primary: HRQoL (Health Related Quality of Life) — 0.08; 0.10 points on a scale

Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 53; 48; 38 Number of Participants

Primary: Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) — -4.7; -4.6 units on a…

Primary: Cumulative Response Rate of 15 or More Letter Improvement — 0.101; 0.092; 0.045; 0.258 Kaplan-Meier Estimate

Primary: Hemagglutination Inhibition (HI) Antibody Titer — 13.6; 11.6; 165.5; 68.2 titer

Primary: Hemagglutination Inhibition (HI) Antibody Titers — 19.5; 13.9; 116.0; 47.1 titer

Primary: Change From Baseline in International Restless Legs Syndrome (IRLS) Total Score at 6 Weeks — -12.3; -12.5; -11.8 Points on a scale

Primary: Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment — 57; 48; 28; 24 Percentage of Subjects — p=0.010

Primary: Change in Brief Pain Inventory (BPI) 24-hour Average Rating — -1.80; -1.12; -2.47; -1.41 units on a scale — p=<0.001

Primary: Number of Patients With Clinical Response of Cure Vs. Failure. — 316; 334; 92; 71 patients

Primary: Percentage of Subjects With Adverse Events of Diarrhea During the First 8 Weeks — 49.1; 54.8; 44.6; 49.7 Percentage of Subjects — p=>0.100